- active not recruitingPHASE1, PHASE2
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This study looks at a new drug, ASTX660, for people with advanced cancers like solid tumours and lymphomas. It checks how safe the drug is, the best dose to use, and if it helps shrink tumours, especially when standard treatments aren't working.
United States · Belgium · Canada - recruitingPHASE3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
This study is looking at a new medicine called duvelisib for people in the UK with a specific type of T-cell lymphoma that has come back or not responded to previous treatments. It compares duvelisib to standard treatments like gemcitabine or bendamustine to see if it helps patients live longer without their cancer getting worse.
Belgium · Czechia · Denmark - active not recruitingPHASE3
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
This study looks at whether adding radiation after chemotherapy helps people with advanced Hodgkin's disease. Researchers want to see if this combination prevents the disease from coming back or helps people live longer, compared to chemotherapy alone.
Belgium · Egypt · France - recruiting
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
This study looks at how we measure physical activity in people with lymphoma, pancreatic, or bowel cancer. It compares questionnaires with motion trackers to see which works best. The aim is to find better ways to understand how active cancer patients are.
Germany - active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This study looks at a new drug, Glofitamab, combined with standard treatment for a type of lymphoma called DLBCL. It aims to see if this new combination is safe and effective for patients who haven't been treated before and have a high-risk form of the disease.
United States · Denmark · France - recruitingPHASE1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
This study is testing a new medicine, TLN-121, for people with certain types of non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Doctors want to see if it's safe, how it works in the body, and if it can help shrink the cancer.
United States · Australia · Canada - active not recruitingPHASE1
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
This study looks at a new treatment for certain types of leukaemia and lymphoma that have come back or not responded to usual treatments. It uses specially modified cells from the patient to target and fight cancer cells more effectively.
United States · Canada - recruitingPHASE2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
This study is looking at a new type of treatment called liso-cel for adults with a brain lymphoma that can't have a stem cell transplant. It aims to see how safe and effective this new treatment is as the first treatment they receive.
United States · France · Germany - recruiting
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
This study looks at a new way to diagnose lymphoma earlier in adults with a serious condition called HLH. By checking for cancer DNA in blood samples, researchers hope to improve treatment and survival for people who develop HLH because of lymphoma.
United Kingdom - recruitingPHASE1, PHASE2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.
Belgium · France · Italy - active not recruitingPHASE3
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
This study looks at different chemotherapy treatments, with or without radiation, for Hodgkin's lymphoma. Researchers want to find the best way to treat this cancer, making sure treatments are effective while reducing side effects.
Belgium · France · Italy - recruiting
Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
This study looks into whether certain gene changes, called CHIP, in older lymphoma patients increase the risk of problems during and after chemotherapy. Researchers aim to understand why some patients struggle with treatment more than others, potentially helping doctors personalise care.
Canada - active not recruiting
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
This study looks at how chemotherapy for breast cancer, lymphoma, or leukaemia can sometimes affect the heart. Researchers want to find out who might be at risk and why, by checking heart health before, during, and after treatment.
Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France - active not recruitingPHASE3
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
This study looks at whether a good bacteria (Lactobacillus plantarum) can help prevent a serious problem called graft versus host disease in children and young adults having a stem cell transplant. Patients will either get the good bacteria or a dummy treatment.
United States · Canada - recruitingNA
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
This study looks at a simple method called Remote Ischaemic PreConditioning (RIPC) to protect the hearts of lymphoma patients receiving chemotherapy. It hopes to see if RIPC can reduce heart problems that sometimes occur with these important cancer treatments.
Denmark · France · Germany - active not recruitingPHASE1, PHASE2
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
This study is testing a new drug called neratinib for children and young adults with cancer that has come back or not responded to other treatments. The main goals are to find a safe dose and understand its effects on the cancer and patients.
United States · Canada - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
This early-stage study is looking at a new medicine called HMPL-523 for people with lymphoma that has come back or not responded to other treatments. The main goals are to check if it's safe, how well the body handles it, and if it shows any signs of working.
Poland - recruitingPHASE1, PHASE2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study looks at a new drug, AZD3470, alone or with other cancer medicines, for people with blood cancers like lymphoma. It aims to see if it's safe, how it works, and if it helps shrink the cancer. This is an early-stage trial.
United States · Australia · China - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
This study is looking at new treatments, relatlimab and nivolumab, for young people (up to 18 years old) with types of blood cancer called Hodgkin Lymphoma and Non-Hodgkin Lymphoma. It checks if they are safe and if they help shrink the cancer when other treatments haven't worked.
Netherlands · Spain · Italy - active not recruitingPHASE3
PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma
This study looks at whether a special scan (PET scan) after chemotherapy can help doctors decide if people with early-stage Hodgkin lymphoma need more treatment, like radiotherapy. It aims to see if some patients can safely avoid extra treatment.
United Kingdom - recruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
United States · Australia · Brazil - active not recruitingPHASE1
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
This study is testing a new discovery medicine called BYON4228, along with an existing medicine called Rituximab. It's for people with a type of blood cancer called lymphoma that hasn't responded well to previous treatments. It aims to see if the new medicine is safe and how well it works.
Italy · Netherlands · Spain - recruitingPHASE1, PHASE2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This study looks at a new drug, repotrectinib, for children and young adults (up to 25) with certain advanced cancers. It checks if the drug is safe and helps shrink tumours that have specific genetic changes called ALK, ROS1, or NTRK.
United States · Australia · Canada